About ASAPQuite simply, ASAP collaborates as a team and with other Angel groups in filling the void in the financial investment marketplace, working together to nurture and harvest great companies.Since our launch in 2005, we have invested a total of $6 million in over 20 deals, many of these in health/life sciences and biotech. A typical year includes screening approximately 20 companies, identifying 6-10 with solid business models for presentation to the full membership, and investing in 3-5 after extensive due diligence performed by a team of members who have expertise or interest in the company's space.Ariel Southeast Angel PartnersASAP_705fc1f2-4407-11e8-a371-de90fbc279adThe Ariel Southeast Angel Partners is a group of angel investors who share senior level business expertise, resources, and a proactive investment philosophy in support of start-up and early stage high growth businesses, both in the Southeast and across the US.ASAP Board of ManagersBeau AndersDirector -- Mr. Anders was the KPMG Office Managing Partner-in-Charge in Silicon Valley as well as the Western Area Partner-in-Charge, of KPMG’s Transaction Services. KPMG’s Silicon Valley office had over 750 employees providing audit, tax and advisory services to technology companies throughout the South Bay. In his managing partner role, Mr. Anders was responsible for all market-facing activities for the firm in Silicon Valley. At the same time, Beau led KPMG’s Western Area Transaction Services practice where his focus was on M&A in high technology. He provided both due diligence and structuring advice to buyers as well as capital advisory services to early stage and middle market companies. Prior to KPMG he spent 12 years in senior level financial positions in industry with several public and private companies, including three medical start-ups. Beau's extensive CFO experience included participation in two initial public offerings and numerous acquisitions of products and businesses in the pharmaceutical and medical technology industries. This experience included responsibility for raising more than $300 million in public and private debt and equity. He has completed well in excess of 100 due diligence engagements on high technology companies.Don BrashearsDirector -- Don Brashears graduated from Rider University with a BS in Commerce in 1976 and received his MBA in International Economics and Finance in 1982. Don is an Owner and Partner in Atlantic Real Estate, Inc., a full service real estate sales and rental company with 200+ individually owned rental units service the Hilton Head Island and Bluffton Communities in South Carolina. Don is a Franchise Owner and Area Developer for Liberty Tax Service, and operates one office in Bluffton and has thirteen offices in Augusta, Georgia and Aiken, South Carolina. There are also seven franchised offices in the Boston Area. In addition, Don owns Seabrook Properties, LLC where he manages a portfolio of personal investment properties. For his first career, Don spent 30 years with US STEEL Corporation in Fairless Hills, PA as Area Manager for Galvanizing, Sheet and Tin Finishing operations, producing products for Chrysler, GM, and Toyota as well as Del Monte, Campbell's Soup and others.Don is the Board Chair for the Greater Bluffton Chamber of Commerce and CVB. He is the President Elect of the Rotary Club of Hilton Head (150+ members) and is a Board Member of the Literacy Center, a non-profit assisting the functionally illiterate and teaching English as a second language. Don has been a member of the Ariel Southeast Angel Partners since 2006 and a Board Member for 2 years.Steve ClarkDirector, Chairman -- Steve has held a wide variety of positions as a lawyer, business executive and entrepreneur. Throughout his career, he has spent significant professional time performing due diligence and negotiating business transactions. As Vice President and General Counsel of Gerber Products Company, Steve was responsible for the development and implementation of legal and regulatory strategy for the Company. Steve's transactional experience at Gerber included the purchase of Alima, SA, one of the first privatizations in Poland. His experience as CEO and President (and prior positions) at Buster Brown Apparel included the successful reorganization of Buster Brown under Chapter 11 of the Bankruptcy Code, and the subsequent sale of key business units to maximize return to shareholders. As Owner of Second Nature LLC, Steve aggressively grew the sales and profitability of a local landscaping company, selling the business in 2009 to ValleyCrest, the country's largest landscape contractor. Steve has served as Chairman of Ariel Savannah Angel Partners for the last three years Steve has served on a number of charitable and civic boards over the years, and is currently Chairman and President of the Deep Well Project on Hilton Head Island. Steve received an Honor's Degree in Economics from Lafayette College, his J.D. Degree from Catholic University Law School, and an LL.M in Trade Regulations from New York University Law School.Courtney FlexonDirector -- Courtney Sprague Flexon graduated from Vanderbilt cum laude in 1977 and received her MBA from the Terry School of Business at UGA in 1980. A Savannah native, from 1996-2004 she served on Savannah City Council as Alderman of the fourth district, and her second term she was unopposed. From 2009-2015 she has served as a Commissioner on the Jasper County SC Planning Commission. In 2004 she was named the first female director of the Adeline Companies, a privately held investment firm that has been in the Sprague and Oxnard families for 124 years. From 2012 to present she has been the President of the Adeline Companies.Courtney has served on numerous boards, including Historic Savannah, the Mediation Center, and the Chatham Foundation. She has served several years on the ASAM board. She and her husband Phillip Flexon MD enjoy gardening and bird hunting, and have a daughter and two rambunctious grandsons who occupy most of their spare time.Carl D FrancisDirector -- Carl D Francis spent eight years as CEO of P2i (www.p2i.com), a technology spin-out from the UK Ministry of Defence. Based in Oxford, England, he built the business from a 10 person, pre-revenue tech start-up with no products, no customers, and no sector focus into the dominate global force in functional nano-coatings today. Many of world’s best known brands now rely on P2i technology solutions, and the Company currently operates across 51 sites in 17 countries. P2i raised over $100m in new equity over a series of funding rounds during this period, and today the Group remains privately held and is substantially profitable. Carl chose to step down as CEO in late 2016, but continues to work with the Company in a strategic advisory role.Before joining P2i in 2008, Carl spent three years as CEO acquiring, running, and successfully exiting Adria Ltd, Ireland’s largest textile business, in an LBO on behalf of a small private equity group in which he was a founding partner. Previously, he was Group Managing Director of the Caudwell Group, Europe’s then biggest privately-owned mobile telecommunications support business with sales of $2.5Bn; Chief Executive of Flexonics, the principal division of global precision engineering group Senior plc; and Divisional President at SIEBE plc (now Invensys plc) where for three years he ran the group’s worldwide recovery division. Carl has also held several Operating Partner and Non-Executive roles, including Chairman of HSD Communications Ltd from 1998 to 2007. Following his seed investment, HSD grew from a one-person start-up into the UK’s 14th largest healthcare PR agency, and was sold to an international advertising group in 2007. Starting his career as a US Certified Public Accountant, Carl is a member of Mensa and has a BSc from the University of Cincinnati. He and his wife Lesley live in the Savannah, Georgia area.Jim GoodlettDirector -- Jim Goodlett is a proactive Executive with proven SMB and Enterprise business success. He has expertise in change management and strategic planning, while leading companies toward innovative products and solutions - this includes moving industries at speed into WEBcentric/SaaS business models while maintaining productivity and increasing revenue opportunities. Jim is also skilled in motivating business verticals that integrate technology into business workflow over tight time-frames, increasing revenue in the business unit, and most importantly for customers using the products/services. His executive positions include VP of Online Learning (Savannah College of Art and Design), Chief Information Architect at H.O Systems (driven revenue from US$16M to US$128M in 3 years and sold for US$356M), Director of Emerging Technologies for US$2.3B in revenue $VS, and he is currently President of Morris Technology.Jim has actively participated on for-profit Boards and in Angel investing with experience that extends to advising on utilizing technology as a strategic weapon, market positioning, and leveraging changes in development processes for quicker time to market products. This includes utilizing agile/SCRUM development workflow for faster time to market productization! He has held Board seats with ASAP, Vendormate (including a 10x investment return upon exit), and IngeniousMed Board at US$110M exit. Jim’s previous and current Board seats include cBETA, Savannah Country Day School, GSU College of Engineering and IT, REELsavannah. He is currently Vice Chair, Board of Directors and fund the 55 year-old Savannah Science Seminar program.Joe IsolaDirector -- Before he retired Joe was a Partner in Woodbury Partners, a small consulting firm based in New England that provided strategic, IT, business development and operational consulting to early stage companies in healthcare and related industries. Prior to that in a thirty year corporate career in the for-profit healthcare field, he served in several capacities including Chairman & CEO of a midsized venture capital backed diagnostic & health services Company; as a President and COO of a NYSE diagnostic services firm and in several other senior roles in the medical diagnostic field, including Division President, Senior Vice President and General Manager, VP of Marketing, Sales and Business Development and as a Regional Director of Sales and Service. During his long corporate career, Joe successfully led the effort to significantly grow the sales and profits of three separate companies. He helped negotiate over forty acquisitions and a half dozen significant joint ventures. Additionally, he participated in or led teams that have raised over $750 million in both equity and debt financing. Finally, for several years he served as the President of the largest national trade organization in the diagnostic services industry, the American Clinical Laboratory Association. Over the years, Joe sat on over a dozen Boards including corporate, university, partnerships and trade group organizations. For the last eight years he has been an active Partner in Ariel Southeast Angel Partners where he sits on their Board of Managers and has been the Chairman of their Investment Committee. Joe has a BA and a Master's Degree in Business with a major in Healthcare Administration and has completed a significant portion of a PhD in organizational behavior.Joe serves as the Chairman of the Medical/Life Sciences Screening Committee.J. Blake Long, MDDirector -- Mosaic Health Solutions is a venture capital firm in Durham NC focused on accelerating healthcare innovation by building partnerships and making strategic investments that will improve the value and effectiveness of the healthcare system. As Chief Clinical Officer, Blake provides strategic input and clinical consultation to business development leadership in order to facilitate the identification and evaluation of compelling investment opportunities with clinical components. Prior to joining Mosaic in August of 2015, Blake served as a practicing physician at Savannah Children’s Heart Center and as a clinical professor at Mercer University School of Medicine. A member of Ariel Southeast Angel Partners since 2011, he serves on the board and has led the management process of screening, due diligence, and company monitoring for the portfolio of investments in healthcare and life sciences. Blake earned his BA and his MD from Duke University. He completed his residency in pediatrics at Walter Reed Army Medical Center, and fellowship in pediatric cardiology at Duke University. He received his MBA from Duke’s Fuqua School of Business in December of 2015, focusing on health care system change at the interface of science, technology, ethics, policy, economics and business.Jack McMakenDirector -- Jack has extensive experience managing marketing, development, and licensing at large medical device and diagnostic companies. Most recently, Jack served 14 years as President and Chief Executive Officer of a Portland, Oregon based medical device company specializing in the development, manufacturing, and licensing of proprietary tissue repair products, and anti-infective technologies to industry leaders including Medline, Baxter, Stryker, Biomet, Bard, Bristol-Myers-Squibb, and Smith & Nephew. Jack successfully prosecuted a patent infringement lawsuit to receive a $26M settlement and turned around and grew this early stage company, eventually selling the company to achieve a very positive exit for employees and investors. Prior to this, Jack spent 28 years with Corning and Kimberly Clark in management positions in marketing, sales, and R&D for medical products including diagnostics, capital equipment, and supplies. He headed up Kimberly Clark’s Business Development Group creating products and businesses and spinning them out.Jack received his B.A. from Vanderbilt University and pursued graduate business studies at the University of Chicago and Boston College. He is now retired and spends his time enjoying being a pilot, volunteer, adventure traveler, and investor. He has been a member of ASAP for 4+ years and has participated as part of six due diligence teams. Bill TausigDirector -- Bill Tausig is the retired Executive Vice President and Chief Financial Officer of CareCore National LLC, a specialty healthcare benefits management company. Mr. Tausig was the Executive Vice President and Chief Financial Officer of CareCore National, LLC from 1999 until 2014, shortly after the Company was acquired by General Atlantic, a leading global growth equity firm. He was earlier Chief Financial Officer of two privately owned startup companies providing behavioral healthcare benefits management services. Prior to his private industry experience, Mr. Tausig served in the audit practice of Price Waterhouse, an international public accounting firm, and responsible for the audit of public and private companies and Merger and Acquisition engagements in various industries. Mr. Tausig passed the CPA examination in Virginia. My Tausig has been an Angel Investor since 2009 and served on the ASAM Board of Director from 2012 to 2015 including serving on the ASAM Executive and Investment Committees. In addition, Mr. Tausig served on the ASAP Medical Screening Committee. Mr. Tausig brings to the Board executive leadership experience including his serving as Chief Financial Officer of three startup companies, extensive healthcare industry experience and debt and equity financing experience.Jerry ThimmeDirector -- Jerry spent 30 years in the institutional investment industry working for several firms, including Prudential Asset Management and Deutsche Bank. His major responsibilities included Strategic Planning, Global Marketing and running several businesses. Jerry’s most recent assignment was as the Head of the Institutional Group at Scudder, Stevens and Clark, reporting to the Chairman and Serving on the Board of Directors. Jerry served 5 years of active duty and 21 years in the Air National Guard, retiring as an Air Force Colonel. His most recent assignment was as Deputy Commander of Resources and Base Commander for a tactical fighter wing overseeing base facilities and resources.Jerry has served on the Boards of several charitable organizations, including the Live Oak Public Library Foundation, The Mighty 8th Museum and the Landings Board of Directors. He has been an active ASAP investor since 2011 and has served on several committees. Jerry has a BS and BA from Bucknell University and an MBA in Finance from St. Mary’s University. He also pursued graduate business courses at Wharton and Northwestern.Camille PopeAdministrative Manager and Treasurer -- Camille Pope is a finance executive with eighteen years of experience in industry and consulting in firms ranging from self-employment to a major financial services institution. As the Principal of Chameleon Financial, LLC, Cam provides financial consulting services to real estate developers and business owners. She has depth and breadth of corporate finance experience with key skills including financial modeling, financial planning, analysis and reporting, strategic planning, real estate underwriting and project management. Prior to founding Chameleon Financial, Cam was the Finance Manager for Melaver, Inc., where she provided financial discipline to sustainable design practices and leveraged financial modeling expertise to provide insight into investment decisions. Before joining Melaver, Cam was a Vice President for LaSalle Bank Corporation, an international financial services institution. She spent seven years working in various finance and corporate development functions in Chicago and Amsterdam.Cam received a Bachelor of Science from The University of Notre Dame in 1998. She earned her MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University in 2004 with concentrations in Finance, Management and Strategy and Entrepreneurship.Neil C. HerringOther Leadership Role -- Due Diligence Manager - Life Sciences --Mr. Herring recently retired after 40 years working in life sciences, clinical services, research management and healthcare IT. His career includes work in accounting, finance, M&A, business development, sales and operations, as well as project management. He has held senior leadership positions in several small companies, a private equity funded start-up and a publicly held company. Most recently he has provided strategy and IT management consulting services to a number of healthcare enterprises and not for profit institutions. He retired as a Corporate Manager for several large research infrastructure projects at an academic medical center in Boston.Mr. Herring has been an active investor with ASAP for 6 years and has participated in due diligence reviews for 5 portfolio companies, among others. He acts as ASAP’s board observer for two portfolio companies.Start-Up VenturesWe are seeking ventures that require funding, as well as knowledgeable input from our members in order to accelerate their growth.We traditionally invest in companies with the potential to exit within 3-5 years.ASAP MembersInquiries from individual investors who would like to join and actively participate in our organization are welcome...As high-net worth individuals, members of our private investment group have an array of senior level business and professional backgrounds in multiple sectors. Members contribute personal capital, as well as energy and expertise, towards funding and guiding innovative, high growth potential, early stage businesses. Members must meet the test of being accredited investors per SEC Regulations. Each member individually decides whether to invest on each deal (typically a minimum investment of $5,000 and increasing in $5000 increments)...Our membership actively invites interested parties to attend one of our ten monthly evening member meetings.EntrepreneursSupporting Entrepreneurs --​We are interested in investing in innovative solutions for defined markets. Our preference is to fund projects that are past the prototype/proof of concept stage and are close to having customers or customer partnerships. We are strong in health/life sciences and biotech but are open to deals in all sectors with a credible proposition.Our process is to review projects and select promising deals for initial screening by knowledgeable members. Those that pass ASAP's screening process will be invited to present at a member meeting where the members will vote on taking the project to due diligence. Those that are successful will lead to an investment call to members and determine the amount of investment ASAP will make.ASAP PortfolioOur Portfolio Companies to DateActX, Inc.(2017) (www.actx.com) ActX is a Seattle-based company focused on Actionable Genomics℠: evidence-based genetic risks that you can do something about, whether it is a medication affected by genetics, or a medical genetic risk such as a specific cancer risk. ActX is a continuous service -- the analysis provided is frequently updated based on the latest evidence.Advanced Liquid Logic, Inc.(2007, 2008, 2009)- successful exit in July 2013 which saw the acquisition of Advanced Liquid Logic (ALL) by Illumina, Inc. (www.liquid-logic.com) and (www.illumina.com) -- ALL is now a wholly owned subsidiary of Illumina Inc., a San Diego based and NASDAQ listed company which makes genetic testing tools. ALL’s proprietary "digital microfluidics" often referred to as "Lab on a Chip diagnostics" was attractive to Illumina for the development of their next generation gene sequencing. ASAP's investments enabled ALL to develop its innovative technology to an impressive and proven level. The technology electrically segments and manipulates small droplets within a sealed disposable cartridge to perform complex laboratory protocols on fluids such as blood, sewage, water, chemicals and solutions.AG - TI, LLC(2014) (www.AGTI.com) AG-TI is a spin out company from our STI investment. It is focused on the agricultural technology and food production systems space and using an expedited strategic partnership model for growing and exiting companies.AMPLYX Pharmaceuticals, Inc.(2011) (www.amplyx.com) Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs with enhanced efficacy and lower toxicity. Amplyx employs a platform approach to improve small molecule drugs by the addition of a second small molecule to an existing drug with initial development areas are in oncology and infectious disease.Bioptigen, Inc.(2008, 2009) (www.bioptigen.com) Bioptigen’s proprietary Envisu™ Spectral Domain Ophthalmic Imaging Systems (SDOIS) use low powered near infrared light to generate depth-resolved images of ocular tissue structures, non-invasively and in real-time. (Sold to Leica Microsystems 2015)Carmell Therapeutics, Inc.(2011, 2014, 2016) (www.carmellrx.com) Carmell is a Pittsburgh, PA firm that is commercializing technology that enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue.Carrot Medical, Inc.(2010) (www.carrotmedical.com) A Seattle integrator of multiple independent diagnostic and procedural imaging sources and patient monitoring systems in simultaneous use during medical procedures. Consolidating information into fewer redundant monitors and displays increases the availability of clinically relevant, real-time data of to the clinical decision-maker, and optimizes space, patient care and economic efficiency.Cognition Therapeutics, Inc.(2014, 2016) (www.cogrx.com) Cog RX is pursuing a unique process for the early detection of Alzheimer’s disease with a potential to treat and reverse the disease.Consortia TX, Inc.(2017) Consortia TX is a biopharmaceutical company that focuses on therapies of human colonizing microbes and microbial products to treat human diseases. The company's first patented consortia have been developed for the prevention and treatment of human food allergies. Other applications are in process.Decision Link, Inc.(2014, 2016) (www.decisionlink.com) A business intelligence sales software system for improving the content packaging of relevant product information and performance evaluation data for justifying the use of systems products in an operational customer setting. Focused on improving the sales closing rates of sales professionals.Embera NeuroTherapeutics, Inc.(2014, 2016) (www.emberaneuro.com) EMBERA is an early stage drug development company that is testing a unique compounding of two existing drugs for the purpose of controlling smoking cessation and drug addiction.FAST Biomedical(2009, 2014, 2015) (www.fastbiomedical.com) An Indianapolis, IN company with a revolutionary new point-of-care system for accurate, sensitive and rapid measurement of kidney function, which is revolutionary in the diagnosis of Acute Kidney Injury.HelixBind, Inc.(2017) (www.helixbind.com) HelixBind is a Massachusetts based company focused on its patent pending Pathogen Identification (PID) platform that will provide rapid detection and unequivocal identification of bloodstream infections, direct from a whole blood specimen and without the need for blood culture. This will allow physicians to quickly adjust to the optimal, targeted, antimicrobial intervention and monitor the effectiveness of that treatment throughout care.LaunchPad Medical(2017) (www.launchpadmedical.com) LaunchPad Medical is an early-stage medical device company that was formed to develop and commercialize Tetranite™, which is a novel bioresorbable bone adhesive technology co-invented by the CEO. The Massachusetts based company aims to develop and manufacture products based on this patented technology. The first product developed from this platform technology is designed for use within the field of implant dentistry.Mellitus(2017) (www.mellitusllc.com) Mellitus is a Boston-based company dedicated to advancing diabetes detection and monitoring through products based on GCD59, a biomarker of glycemic load that is unique because of its direct relationship to the complications of diabetes. The company’s premier application is a patient-friendly test for gestational diabetes, enabling more timely intervention to improve the health of both mother and child.Monitor Mask, Inc.(2016) (www.monitormask.com) Monitor Mask is a Bellevue, Washington medical device company founded with the mission of creating capnography oxygen face masks to increase patient safety and streamline workflows. The first design, the M1 Capnography Mask, was imagined in the spring of 2011 and served as the inspiration for the CapnoVue face mask series. CapnoVue devices facilitate capnography in medical practice, increase patient safety, make care workflows more efficient, and help clinicians meet monitoring standards.NeurOP, Inc.(2007, 2009, 2011) (www.neuropinc.com) NeurOp, Inc. is a biopharmaceutical company developing new medicines to treat central nervous system disorders, including major depression, neuropathic pain and ischemia. Our mission is to develop a new generation of N-methyl-D-aspartate (NMDA) receptor blockers, which inhibit proteins that play an important role in neuron signaling. Our compounds specifically target the NR2B subtype of these receptors offering an unprecedented opportunity to improve the safety and tolerability of this therapeutic class without compromising efficacy.New Wave Surgical(2010, 2011) (www.newwavesurgical.com) New Wave Surgical Corp. (NWS) is a premier medical device development company working to design, patent and market medical devices for laparoendoscopic surgical markets. Our first exciting innovation was D-H.E.L.P.®–the only endoscopic visualization system that keeps the laparoscopic lens defogged and clean from the start of surgery to close. NWS was acquired by Covidien, Inc. in a cash buyout in July 2014.NorthShore Bio(2015, 2016) (www.northsorebio.com) NorthShore Bio is a life sciences tools and services company that focuses on the development of direct-to-digital™ nanopore chips, instrumentation appliances, and low-cost sequencing services that enable a range of tests, from simple to data-rich, making sequencing faster, simpler, and more accessible to researchers, clinicians, and field practitioners. NSB's platform changes the "molecular information" problem with the development of proprietary silicon-based, label-free direct electrical sensors that enable significant advances in the resolution and speed of molecular measurement. For example, the chip's proprietary silicon nanopores can be tuned, or sized, electronically to dimensions that will allow for selective identification of DNA, RNA, small molecules, and ion flow.Optima Neuroscience(2010) (www.optimaneuro.com) A Gainesville, FL medical device company producing a line of revolutionary brain monitoring products designed for use in hospital intensive care units and emergency rooms. The unit is a wearable head cap with built-in sensors couples to a monitor with software that can predict possible stroke events and provide early warning for proactive intervention. (Optima Neuroscience was acquired by its key distributor in a cash buyout in 2011.)OrthoPediatrics, Inc.(2009) (www.orthopediatrics.com)– OrthoPediatrics is the first company whose total focus is helping children with orthopedic conditions and injuries by providing the surgeons who care for them with anatomically appropriate implants.R and R Music, Inc.(2009, 2010) (www.randrmusic.com) (Originally Music Intelligence Solutions, Inc.) A Savannah, GA company with operations in CA and Spain with IP to predict a new music pieces success potential of becoming a hit. Scores and compares music to a deductive universe of prior hits. Now actively selling a rating service to the music writing industry that couples to an on-line marketing and distribution service for high scoring music products. Merger moved operations to Scotland, UK.Respiratory Motion(2012, 2014, 2016) (www.respiratorymotion.com) -Respiratory Motion, Inc. (RMI) is a new generation medical device company developing and commercializing the ExSpironTM. a noninvasive, continuous respiratory monitor which has received FDA clearance to graphically display lung volumes against time in a wide variety of patients, which more adequately predicts ventilatory distress and cost-effectively improves the standard of care in respiration monitoring.Southeast TechInventures, Inc.(2007, 2009, 2010) (www.southeasttechinventures.com) Located in Durham, NC, STI mission is to build an effective and profitable technology accelerator for rapid conversion of scientific breakthroughs into products, services and new technology companies. STI partners with inventors to accelerate the commercialization of technologies and intellectual property (IP). Our current focus areas include medical devices, diagnostics, biotechnology, nanotechnology, materials, electronics, and agriculture including agricultural biotechnology.Virginia Distillery Company(2010) (www.VADistillery.com) A Dixon Country, VA niche producer and marketer of high-end malt liquor to be made in a new Virginia distillery with single and double malt products._705fc530-4407-11e8-a371-de90fbc279adTo accelerate the growth of ventures that require funding and knowledgeable input from our members_705fc706-4407-11e8-a371-de90fbc279adExpertise & ResourcesShare senior level business expertise, resources, and a proactive investment philosophy in support of start-up and early stage high growth businesses, both in the Southeast and across the US._705fc85a-4407-11e8-a371-de90fbc279ad_705fc9f4-4407-11e8-a371-de90fbc279ad2018-04-19http://www.arielsoutheastangels.com/index.htmlOwenAmburOwen.Ambur@verizon.net